InMed Pharmaceuticals (INM) Share-based Compensation (2019 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Share-based Compensation of $109344.0 for Q1 2026, up 370.29% year-over-year from $23250.2 in Q1 2025, and up 532.81% quarter-over-quarter from -$25264.0 in Q4 2025.
InMed Pharmaceuticals (INM) Share-based Compensation (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $109344.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 370.29% year-over-year to $109344.0; the TTM figure through Mar 2026 stood at $109344.0 (up 303.92% YoY), while the FY2025 annual figure was $72549.0, down 47.32% from the prior year.
- Share-based Compensation for Q1 2026 stood at $109344.0, up from -$25264.0 in the prior quarter.
- The five-year high for Share-based Compensation was $195085.0 in Q1 2022, with the low at -$413329.0 in Q2 2023.
- The 5-year median for Share-based Compensation is $25191.0 (2023), against an average of $14218.8.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation tumbled 333.67% in 2023, then surged 370.29% in 2026.
- InMed Pharmaceuticals' Share-based Compensation stood at $70638.0 in 2022, then slumped by 74.14% to $18264.0 in 2023, then tumbled by 226.8% to -$23159.0 in 2024, then decreased by 9.09% to -$25264.0 in 2025, then jumped by 532.81% to $109344.0 in 2026.
- Business Quant data shows INM's Share-based Compensation at $109344.0 in Q1 2026, -$25264.0 in Q4 2025, and -$20205.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.56 Mn | 1.32 Mn | - | 38,771.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109,344.00 |
| Mar 31, 2026 | 109,344.00 |
| Dec 31, 2025 | -25,264.00 |
| Dec 31, 2025 | -25,264.00 |
| Sep 30, 2025 | -20,205.00 |
| Sep 30, 2025 | -20,205.00 |
| Jun 30, 2025 | -63,613.00 |
| Jun 30, 2025 | -63,613.00 |
| Mar 31, 2025 | -40,454.00 |
| Mar 31, 2025 | -40,454.00 |
| Dec 31, 2024 | -23,159.00 |
| Dec 31, 2024 | -23,159.00 |
| Sep 30, 2024 | -28,964.00 |
| Sep 30, 2024 | -28,964.00 |
| Jun 30, 2024 | 38,955.00 |
| Jun 30, 2024 | 38,955.00 |
| Mar 31, 2024 | 55,305.00 |
| Mar 31, 2024 | 55,305.00 |
| Dec 31, 2023 | 18,264.00 |
| Dec 31, 2023 | 18,264.00 |